# Do GLP-1 Drugs Help Migraine? Triptan Use Fell 7%, Which Is Not a Treatment Do GLP-1 drugs help migraine? A 189,392-person Danish register found triptan dispensing down 7% at twelve months, and an interrupted time series has no control group. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-migraine Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Migraine? Triptan Use Fell 7%, Which Is Not a Treatment A Danish register of 189,392 people found triptan dispensing fell after semaglutide was started. The effect is real, small, and sits inside a study design with no control group. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Triptan dispensing, defined daily doses · first dispensing · 24 months before · −7% at 12 months **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Not enough to buy one for headaches. A Danish register followed 189,392 adults starting semaglutide for weight management [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-migraine#ref-1). Triptan dispensing had been rising. After initiation the trend reversed. The reduction was 7% at twelve months, RR = 0.93, 95% CI 0.88 to 0.97. It came from people already taking triptans, not from fewer people starting them. Women fell 8%. In men the change was not statistically significant. There is no control group in that design. ## Key takeaways - A Danish register study followed 189,392 adults starting semaglutide for weight management. - Triptan dispensing had been rising. After initiation the trend reversed. - The reduction was 7% at twelve months — a rate ratio of RR = 0.93, 95% CI 0.88 to 0.97. - It came from people already taking triptans, not from fewer people starting them. - Women showed an 8% reduction. In men the change was not statistically significant. Migraine and obesity are linked, and both are common. So the question is old and the data are new. Denmark keeps national prescription registers. Somebody used them. ## What was measured Everyone who started semaglutide for weight management between December 2022 and December 2024 was included. That is 189,392 adults, 68% women, median age 50. Each person’s first dispensing set the clock. The study looked back 24 months and forward 12. [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-migraine#ref-1) The outcome was triptan consumption, counted in defined daily doses per 10,000 people per month. Note what that is. Triptans treat an attack that has already started. Dispensing them is a proxy for how often attacks happen. It is a good proxy and it is not the thing itself, a distinction [endpoint choice makes constantly](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## The result Before initiation, triptan use was climbing. After it, the trend reversed. The decline was 13 defined daily doses per month per 10,000 people (95% CI −25 to −1.3). At twelve months that came to a 7% relative reduction — a rate ratio of RR = 0.93, 95% CI 0.88 to 0.97. Where it came from matters more than the headline. Existing triptan users cut their consumption: RR = 0.86, 95% CI 0.82 to 0.90. The monthly rate of new triptan users barely moved. So this is people who already had migraine using less, not fewer people developing it. The subgroups split cleanly. Women fell 8%: RR = 0.92, 95% CI 0.88 to 0.97. Men showed no statistically significant change. The largest reductions were in people aged 18 to 35, at RR = 0.86, 95% CI 0.78 to 0.94. People who had previously taken a migraine preventive came in at RR = 0.88, 95% CI 0.82 to 0.94. Who wrote this Two of the authors are employed by Novo Nordisk, which manufactures semaglutide. A third reports sponsor-initiated research funded by the same company, paid to his institution. All of that is disclosed in the paper. It does not make a national register of 189,392 people wrong. It is a fact you should have before you weigh a seven percent finding published by a manufacturer’s employees. ## The two neighboring neurological readings Two other results sit beside this one. A meta-analysis of 9 studies and 13,257 participants looked at idiopathic intracranial hypertension [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-migraine#ref-2). Its main symptom is headache, and the comparator was conventional management. Headache came in at RR 0.73 and papilledema at RR 0.38. The same analysis reports 80% lower mortality, RR 0.20, 95% CI 0.07 to 0.59. That figure is not plausible as a drug effect. Whatever produced it is also acting on the headache number, which is the reading in [the mortality number that cannot be right](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension). The wider neuropsychiatric pooling is more disciplined. A systematic review screened 10,037 records and pooled 82 studies, graded with GRADE [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-migraine#ref-3). Risk of developing Parkinson’s disease was lower, pooled HR 0.70, 95% CI 0.53 to 0.92, from observational studies. Motor symptoms in people who already had it did not improve, mean difference −3.29, 95% CI −7.84 to 1.26, from trials. Prevention and treatment are separate questions. That split is set out in [preventing it is not treating it](https://thisglp.com/research/preventing-it-is-not-treating-it). ## What the design cannot rule out An interrupted time series compares a population to its own past. There is no control group. Everything else that happens when somebody starts a weight-loss drug happens inside the measurement window. People who start these drugs lose weight. They often eat differently and sleep differently. Many are titrating upward through the same months, which [changes more than the dose](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it). Some stop other medications. Some are seeing a clinician regularly for the first time in years. Any of those could move triptan dispensing on its own. The study cannot separate them, and it does not claim to. There is also a plainer possibility. Nausea is common early on. A person feeling sick may fill fewer prescriptions of anything. The effect here was gradual rather than abrupt, which argues against that, but it is not excluded. ## Is seven percent worth anything On its own, no. Seven percent of triptan consumption is not a migraine treatment. The approved preventives do far better and they are cheap. Nobody should buy this drug for headaches. As a secondary benefit it is more interesting. If you are taking the drug anyway and you have migraine, this is a modest reason to expect less. That is the honest frame, and it is the frame [most real-world findings deserve](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). The money question is simpler. These drugs are priced for weight loss, and a headache benefit does not change what a month costs. You can see the range in [the price check](https://thisglp.com/tools/glp1-price-check). Nothing on this roster is sold for migraine, and no seller claims it. ## Frequently asked Do GLP-1 drugs help migraine? A Danish register of 189,392 people found triptan dispensing 7% lower at twelve months after semaglutide was started, RR = 0.93. That is a small secondary signal from a design with no control group, not a migraine treatment. Does semaglutide treat migraine? It is not a migraine drug and is not sold as one. A register study found 7% less triptan dispensing at twelve months, which is a small secondary signal rather than a treatment effect. Why triptans rather than migraine attacks? Registers record dispensing, not symptoms. Triptan consumption tracks how often attacks are treated, which follows attack frequency but is not the same measurement. Why did men show no effect? The study does not say. It reports an 8% reduction in women and no statistically significant change in men. The cohort was 68% female, so the male subgroup was also smaller. Who funded it? Two authors are employed by Novo Nordisk, which makes semaglutide, and a third reports sponsor-initiated research funded by the company. The paper discloses this. ## Sources 1. \[1\] Roland N, et al. (2026). Impact of semaglutide introduction on the use of triptans: an interrupted-time series The Journal of Headache and Pain. [PMID 42557547](https://pubmed.ncbi.nlm.nih.gov/42557547/) 2. \[2\] Ahmed W, Gandhi OH, Yu N, Brant J, et al. (2026). Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis Journal of the Neurological Sciences. [PMID 41468715](https://pubmed.ncbi.nlm.nih.gov/41468715/) 3. \[3\] Choudhury I, Ward JH, Mahesh S, Alam U, Azmi S, Anson M (2026). Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis Clinical Therapeutics. [PMID 41862354](https://pubmed.ncbi.nlm.nih.gov/41862354/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)